CYP3A5 | Human | (+)-catechin | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA | CTD | PMID:25663641 |
CYP3A5 | Human | (+)-epicatechin-3-O-gallate | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA | CTD | PMID:25663641 |
CYP3A5 | Human | (+)-Tetrandrine | increases glutathionylation | EXP | | 6480464 | CYP3A5 protein results in increased glutathionylation of tetrandrine | CTD | PMID:21992520 |
CYP3A5 | Human | (+)-Tetrandrine | multiple interactions | EXP | | 6480464 | CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione] more ... | CTD | PMID:26302866 |
CYP3A5 | Human | (+)-Tetrandrine | increases response to substance | EXP | | 6480464 | CYP3A5 protein results in increased susceptibility to tetrandrine | CTD | PMID:26302866 |
CYP3A5 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA | CTD | PMID:25663641 |
CYP3A5 | Human | (1->4)-beta-D-glucan | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of CYP3A13 mRNA | CTD | PMID:36331819 |
CYP3A5 | Human | (R,R,R)-alpha-tocopherol | multiple interactions | EXP | | 6480464 | alpha-Tocopherol inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone] | CTD | PMID:31102695 |
CYP3A5 | Human | (R,R,R)-alpha-tocopherol | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | alpha-Tocopherol results in increased expression of CYP3A13 mRNA and alpha-Tocopherol results in increased expression of CYP3A13 protein | CTD | PMID:26102010 |
CYP3A5 | Human | 1,1,1-Trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of 1 more ... | CTD | PMID:12167570 |
CYP3A5 | Human | 1,2-dichloroethane | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | ethylene dichloride results in increased expression of CYP3A13 mRNA | CTD | PMID:28960355 |
CYP3A5 | Human | 1,2-dimethylhydrazine | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of CYP3A13 mRNA | CTD | PMID:22206623 |
CYP3A5 | Human | 1,4-naphthoquinone | increases abundance | EXP | | 6480464 | CYP3A5 protein results in increased abundance of 1 and 4-naphthoquinone | CTD | PMID:16243959 |
CYP3A5 | Human | 1,8-cineole | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Eucalyptol | CTD | PMID:15715982 |
CYP3A5 | Human | 1-aminobenzotriazole | multiple interactions | EXP | | 6480464 | 1-aminobenzotriazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] | CTD | PMID:24555085 |
CYP3A5 | Human | 1-hydroxymidazolam | increases chemical synthesis | EXP | | 6480464 | CYP3A5 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam | CTD | PMID:18191104 and PMID:26958860 |
CYP3A5 | Human | 1-hydroxymidazolam | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam and erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] | CTD | PMID:34189909 |
CYP3A5 | Human | 1-naphthol | increases abundance | EXP | | 6480464 | CYP3A5 protein results in increased abundance of 1-naphthol | CTD | PMID:16243959 |
CYP3A5 | Human | 1-naphthyl isothiocyanate | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 1-Naphthylisothiocyanate results in decreased expression of CYP3A9 mRNA | CTD | PMID:25380136 and PMID:30723492 |
CYP3A5 | Human | 17alpha-ethynylestradiol | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Ethinyl Estradiol | CTD | PMID:15304426 |
CYP3A5 | Human | 17alpha-ethynylestradiol | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Ethinyl Estradiol results in increased expression of CYP3A13 mRNA | CTD | PMID:17108234 |
CYP3A5 | Human | 17beta-estradiol | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA | CTD | PMID:32741896 |
CYP3A5 | Human | 17beta-estradiol | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Estradiol results in decreased expression of CYP3A9 mRNA | CTD | PMID:35192832 |
CYP3A5 | Human | 17beta-estradiol | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Estradiol results in increased expression of CYP3A13 mRNA | CTD | PMID:39298647 |
CYP3A5 | Human | 17beta-estradiol 3-benzoate | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA | CTD | PMID:32741896 |
CYP3A5 | Human | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [3 more ... | CTD | PMID:16984957 |
CYP3A5 | Human | 2,2',4,4',5,5'-hexachlorobiphenyl | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:21851831 |
CYP3A5 | Human | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:21851831 |
CYP3A5 | Human | 2,2',4,4'-Tetrabromodiphenyl ether | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 2 more ... | CTD | PMID:20566336 |
CYP3A5 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CYP3A13 mRNA and Tetrachlorodibenzodioxin results in decreased expression of CYP3A9 mRNA | CTD | PMID:16054898 more ... |
CYP3A5 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of CYP3A13 mRNA | CTD | PMID:21570461 and PMID:26377647 |
CYP3A5 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:16214954 more ... |
CYP3A5 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CYP3A13 mRNA | CTD | PMID:16984957 more ... |
CYP3A5 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP3A5 mRNA | CTD | PMID:20106945 more ... |
CYP3A5 | Human | 2,4,6-trinitrobenzenesulfonic acid | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Trinitrobenzenesulfonic Acid results in decreased expression of CYP3A13 mRNA | CTD | PMID:17982090 |
CYP3A5 | Human | 2,4-dibromophenyl 2,4,5-tribromophenyl ether | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:38648751 |
CYP3A5 | Human | 2,4-dinitrotoluene | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 2 and 4-dinitrotoluene affects the expression of CYP3A13 mRNA | CTD | PMID:21346803 |
CYP3A5 | Human | 2,6-di-tert-butyl-4-methylphenol | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Butylated Hydroxytoluene results in increased expression of CYP3A9 mRNA | CTD | PMID:18539377 |
CYP3A5 | Human | 2,6-dinitrotoluene | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 2 and 6-dinitrotoluene affects the expression of CYP3A13 mRNA | CTD | PMID:21346803 |
CYP3A5 | Human | 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile | decreases activity | EXP | | 6480464 | Verapamil results in decreased activity of CYP3A5 protein | CTD | PMID:15689501 |
CYP3A5 | Human | 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Verapamil results in decreased expression of CYP3A9 mRNA | CTD | PMID:17973928 |
CYP3A5 | Human | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 3 more ... | CTD | PMID:20959002 |
CYP3A5 | Human | 3,3',4,4',5-pentachlorobiphenyl | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [3 more ... | CTD | PMID:16984957 |
CYP3A5 | Human | 3-methylcholanthrene | multiple interactions | EXP | | 6480464 | AHR protein affects the reaction [Methylcholanthrene results in increased expression of CYP3A5 mRNA] | CTD | PMID:33408298 |
CYP3A5 | Human | 3-methylcholanthrene | increases expression | EXP | | 6480464 | Methylcholanthrene results in increased expression of CYP3A5 mRNA | CTD | PMID:33408298 |
CYP3A5 | Human | 4'-tert-Butyl-2',6'-dimethyl-3',5'-dinitroacetophenone | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | musk ketone results in increased expression of CYP3A9 mRNA | CTD | PMID:9441723 |
CYP3A5 | Human | 4,4'-diaminodiphenylmethane | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 4 and 4'-diaminodiphenylmethane results in decreased expression of CYP3A9 mRNA | CTD | PMID:25380136 |
CYP3A5 | Human | 4,4'-diaminodiphenylmethane | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | 4 and 4'-diaminodiphenylmethane results in increased expression of CYP3A13 mRNA | CTD | PMID:18648102 |
CYP3A5 | Human | 4,4'-sulfonyldiphenol | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | bisphenol S affects the expression of CYP3A13 mRNA | CTD | PMID:39298647 |
CYP3A5 | Human | 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1 and 2-diphenyl-1-butene | CTD | PMID:29285606 |
CYP3A5 | Human | 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1 more ... | CTD | PMID:29285606 |
CYP3A5 | Human | 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol | increases abundance | EXP | | 6480464 | CYP3A5 protein results in increased abundance of 1-(4-hydroxyphenyl)-1 and 2-diphenyl-1-butene | CTD | PMID:29285606 |
CYP3A5 | Human | 4-Hydroxy-N-desmethyltamoxifen | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of 4-hydroxy-N-desmethyltamoxifen] which results in increased abundance of 4-hydroxy-N-desmethyltamoxifen metabolite | CTD | PMID:29285606 |
CYP3A5 | Human | 4-Hydroxy-N-desmethyltamoxifen | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of 4-hydroxy-N-desmethyltamoxifen | CTD | PMID:29285606 |
CYP3A5 | Human | 4-hydroxymidazolam | increases chemical synthesis | EXP | | 6480464 | CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam | CTD | PMID:18191104 |
CYP3A5 | Human | 4-hydroxymidazolam | multiple interactions | EXP | | 6480464 | diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] and Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] | CTD | PMID:18191104 |
CYP3A5 | Human | 5-aza-2'-deoxycytidine | multiple interactions | EXP | | 6480464 | Decitabine inhibits the reaction [Smoke results in decreased expression of CYP3A5 mRNA] | CTD | PMID:21095227 |
CYP3A5 | Human | 5-hydroxydiclofenac | multiple interactions | EXP | | 6480464 | [CYP3A5 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 5-hydroxydiclofenac | CTD | PMID:24246759 |
CYP3A5 | Human | 5-Hydroxythalidomide | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide and CYP3A5 protein results in increased oxidation of and results in increased glutathionylation of 5-hydroxythalidomide | CTD | PMID:20443640 |
CYP3A5 | Human | 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Omeprazole affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole | increases expression | EXP | | 6480464 | Omeprazole results in increased expression of CYP3A5 mRNA | CTD | PMID:19118567 |
CYP3A5 | Human | 6-propyl-2-thiouracil | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Propylthiouracil affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of CYP3A9 mRNA | CTD | PMID:24780913 and PMID:25825206 |
CYP3A5 | Human | 6beta-hydroxytestosterone | increases chemical synthesis | EXP | | 6480464 | CYP3A5 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone | CTD | PMID:26239802 |
CYP3A5 | Human | 6beta-hydroxytestosterone | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone more ... | CTD | PMID:26239802 more ... |
CYP3A5 | Human | 8-Br-cAMP | decreases expression | EXP | | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA | CTD | PMID:22079614 |
CYP3A5 | Human | acetamide | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | acetamide results in decreased expression of CYP3A9 mRNA | CTD | PMID:31881176 |
CYP3A5 | Human | aconitine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Aconitine | CTD | PMID:21277363 |
CYP3A5 | Human | aconitine | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of Aconitine] which results in increased chemical synthesis of 16-O-demethylaconitine | CTD | PMID:21277363 |
CYP3A5 | Human | acrylamide | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Acrylamide results in increased expression of CYP3A9 mRNA | CTD | PMID:15749267 |
CYP3A5 | Human | actinomycin D | multiple interactions | EXP | | 6480464 | Dactinomycin inhibits the reaction [U 0126 results in increased expression of CYP3A5 mRNA] | CTD | PMID:24819614 |
CYP3A5 | Human | afimoxifene | decreases activity | EXP | | 6480464 | afimoxifene results in decreased activity of CYP3A5 protein | CTD | PMID:12419016 |
CYP3A5 | Human | afimoxifene | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of afimoxifene] which results in increased abundance of afimoxifene metabolite | CTD | PMID:29285606 |
CYP3A5 | Human | afimoxifene | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of afimoxifene | CTD | PMID:29285606 |
CYP3A5 | Human | aflatoxin B1 | increases activity | EXP | | 6480464 | CYP3A5 protein results in increased activity of Aflatoxin B1 | CTD | PMID:15454734 |
CYP3A5 | Human | aflatoxin B1 | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Aflatoxin B1 results in decreased expression of CYP3A9 mRNA | CTD | PMID:33354967 |
CYP3A5 | Human | aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of CYP3A5 mRNA | CTD | PMID:22100608 more ... |
CYP3A5 | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of CYP3A5 mRNA | CTD | PMID:21632981 and PMID:21994236 |
CYP3A5 | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of CYP3A5 protein | CTD | PMID:20106945 |
CYP3A5 | Human | Aflatoxin G1 | increases response to substance | EXP | | 6480464 | CYP3A5 protein results in increased susceptibility to aflatoxin G1 | CTD | PMID:11189750 |
CYP3A5 | Human | aldehydo-D-glucose | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CYP3A13 mRNA | CTD | PMID:37567420 |
CYP3A5 | Human | alfentanil | multiple interactions | EXP | | 6480464 | CYB5A protein promotes the reaction [CYP3A5 protein affects the metabolism of Alfentanil] more ... | CTD | PMID:15557344 and PMID:15731592 |
CYP3A5 | Human | alfentanil | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Alfentanil | CTD | PMID:15557344 more ... |
CYP3A5 | Human | all-trans-retinoic acid | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Tretinoin results in increased expression of CYP3A9 mRNA | CTD | PMID:24977338 |
CYP3A5 | Human | alpha-tocotrienol | multiple interactions | EXP | | 6480464 | tocotrienol more ... | CTD | PMID:31102695 |
CYP3A5 | Human | alpha-tocotrienol | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to tocotrienol and alpha | CTD | PMID:31102695 |
CYP3A5 | Human | alprazolam | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Alprazolam | CTD | PMID:15903124 |
CYP3A5 | Human | amiodarone | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Amiodarone affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | amiodarone | decreases response to substance | EXP | | 6480464 | CYP3A5 protein results in decreased susceptibility to Amiodarone | CTD | PMID:26477383 |
CYP3A5 | Human | amitriptyline | increases metabolic processing | EXP | | 6480464 | Amitriptyline results in increased metabolism of CYP3A5 protein | CTD | PMID:18359012 |
CYP3A5 | Human | amlodipine | affects response to substance | EXP | | 6480464 | CYP3A5 gene affects the susceptibility to Amlodipine | CTD | PMID:22149319 |
CYP3A5 | Human | ammonium chloride | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Ammonium Chloride affects the expression of CYP3A9 mRNA | CTD | PMID:16483693 |
CYP3A5 | Human | amodiaquine | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine | CTD | PMID:31629065 |
CYP3A5 | Human | amodiaquine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Amodiaquine | CTD | PMID:31629065 |
CYP3A5 | Human | antimycin A | increases expression | EXP | | 6480464 | Antimycin A results in increased expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of CYP3A5 mRNA | CTD | PMID:24449571 |
CYP3A5 | Human | Aroclor 1254 | increases expression | EXP | | 6480464 | Chlorodiphenyl (54% Chlorine) results in increased expression of CYP3A5 mRNA | CTD | PMID:17851650 |
CYP3A5 | Human | arotinoid acid | multiple interactions | EXP | | 6480464 | [4-(2-(5 more ... | CTD | PMID:34480604 |
CYP3A5 | Human | arsane | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA | CTD | PMID:32525701 |
CYP3A5 | Human | arsenic atom | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA | CTD | PMID:32525701 |
CYP3A5 | Human | atazanavir sulfate | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA | CTD | PMID:33819548 |
CYP3A5 | Human | atrazine | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | Lycopene inhibits the reaction [Atrazine results in increased expression of CYP3A13 mRNA] | CTD | PMID:36216167 |
CYP3A5 | Human | atrazine | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Atrazine results in increased expression of CYP3A13 mRNA | CTD | PMID:36216167 |
CYP3A5 | Human | Azoxymethane | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA | CTD | PMID:29950665 |
CYP3A5 | Human | azoxystrobin | increases expression | EXP | | 6480464 | azoxystrobin results in increased expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | beclomethasone | multiple interactions | EXP | | 6480464 | 1-aminobenzotriazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] more ... | CTD | PMID:12538830 and PMID:24555085 |
CYP3A5 | Human | beclomethasone | increases expression | EXP | | 6480464 | Beclomethasone results in increased expression of CYP3A5 mRNA | CTD | PMID:12538830 more ... |
CYP3A5 | Human | Benoxacor | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | benoxacor results in decreased expression of CYP3A13 mRNA | CTD | PMID:34850242 |
CYP3A5 | Human | benzbromarone | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Benzbromarone affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of CYP3A5 mRNA | CTD | PMID:20106945 more ... |
CYP3A5 | Human | benzo[a]pyrene | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of CYP3A13 mRNA and Benzo(a)pyrene results in increased expression of CYP3A13 protein | CTD | PMID:20127859 and PMID:34472326 |
CYP3A5 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of CYP3A5 mRNA | CTD | PMID:32234424 |
CYP3A5 | Human | benzo[a]pyrene diol epoxide I | increases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:19150397 |
CYP3A5 | Human | benzo[a]pyrene diol epoxide I | decreases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:20018196 |
CYP3A5 | Human | Benzo[k]fluoranthene | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | benzo(k)fluoranthene results in decreased expression of CYP3A13 mRNA | CTD | PMID:26377693 |
CYP3A5 | Human | beta-lapachone | decreases expression | EXP | | 6480464 | beta-lapachone results in decreased expression of CYP3A5 mRNA | CTD | PMID:38218311 |
CYP3A5 | Human | beta-naphthoflavone | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of CYP3A13 mRNA | CTD | PMID:18164116 |
CYP3A5 | Human | beta-naphthoflavone | decreases expression | EXP | | 6480464 | beta-Naphthoflavone results in decreased expression of CYP3A5 mRNA | CTD | PMID:33263786 |
CYP3A5 | Human | bis(2-ethylhexyl) phthalate | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Diethylhexyl Phthalate results in increased expression of CYP3A9 mRNA | CTD | PMID:19850644 |
CYP3A5 | Human | bis(2-ethylhexyl) phthalate | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Diethylhexyl Phthalate results in decreased expression of CYP3A9 mRNA | CTD | PMID:35970509 |
CYP3A5 | Human | bis(2-ethylhexyl) phthalate | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of CYP3A13 mRNA] | CTD | PMID:19850644 |
CYP3A5 | Human | bis(2-ethylhexyl) phthalate | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Diethylhexyl Phthalate results in increased expression of CYP3A13 mRNA and Diethylhexyl Phthalate results in increased expression of CYP3A5 mRNA | CTD | PMID:19850644 and PMID:39109301 |
CYP3A5 | Human | bis(2-ethylhexyl) phthalate | decreases expression | EXP | | 6480464 | Diethylhexyl Phthalate results in decreased expression of CYP3A5 mRNA | CTD | PMID:31163220 |
CYP3A5 | Human | bisphenol A | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of bisphenol A | CTD | PMID:21402134 |
CYP3A5 | Human | bisphenol A | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of CYP3A5 mRNA and bisphenol A results in decreased expression of CYP3A9 mRNA | CTD | PMID:25181051 more ... |
CYP3A5 | Human | bisphenol A | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of bisphenol A] which results in increased chemical synthesis of hydroquinone | CTD | PMID:21402134 |
CYP3A5 | Human | bisphenol F | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | bisphenol F results in increased expression of CYP3A13 mRNA | CTD | PMID:38685157 |
CYP3A5 | Human | bromobenzene | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | bromobenzene results in decreased expression of CYP3A9 mRNA | CTD | PMID:17538237 |
CYP3A5 | Human | bromuconazole | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | bromuconazole results in increased expression of CYP3A9 mRNA | CTD | PMID:33789219 |
CYP3A5 | Human | budesonide | increases expression | EXP | | 6480464 | Budesonide results in increased expression of CYP3A5 mRNA | CTD | PMID:12538830 and PMID:24555085 |
CYP3A5 | Human | budesonide | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Budesonide results in increased expression of CYP3A9 mRNA | CTD | PMID:19562681 and PMID:20888898 |
CYP3A5 | Human | budesonide | multiple interactions | EXP | | 6480464 | Ketoconazole inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA] and Mifepristone inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA] | CTD | PMID:12538830 and PMID:24555085 |
CYP3A5 | Human | bupivacaine | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA | CTD | PMID:22341215 |
CYP3A5 | Human | buspirone | increases oxidation | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of Buspirone | CTD | PMID:15640381 |
CYP3A5 | Human | buspirone | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Buspirone results in increased expression of CYP3A9 mRNA | CTD | PMID:24136188 |
CYP3A5 | Human | butyric acid | increases expression | EXP | | 6480464 | Butyric Acid results in increased expression of CYP3A5 mRNA | CTD | PMID:30439556 |
CYP3A5 | Human | cadmium dichloride | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Cadmium Chloride affects the expression of CYP3A9 mRNA | CTD | PMID:22110744 |
CYP3A5 | Human | calciol | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Cholecalciferol | CTD | PMID:16207822 |
CYP3A5 | Human | calcitriol | increases expression | EXP | | 6480464 | Calcitriol results in increased expression of CYP3A5 mRNA | CTD | PMID:16002434 more ... |
CYP3A5 | Human | calcitriol | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of CYP3A5 mRNA | CTD | PMID:21592394 |
CYP3A5 | Human | cannabidiol | decreases activity | EXP | | 6480464 | Cannabidiol results in decreased activity of CYP3A5 protein | CTD | PMID:24667653 |
CYP3A5 | Human | carbamazepine | increases expression | EXP | | 6480464 | Carbamazepine results in increased expression of CYP3A5 mRNA | CTD | PMID:12673034 |
CYP3A5 | Human | carbon nanotube | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 and PMID:25620056 |
CYP3A5 | Human | carbosulfan | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of carbosulfan | CTD | PMID:20307514 |
CYP3A5 | Human | carfentanil | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of carfentanil | CTD | PMID:33652071 |
CYP3A5 | Human | carmustine | multiple interactions | EXP | | 6480464 | CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] | CTD | PMID:16087946 |
CYP3A5 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to CYP3A5 gene] | CTD | PMID:28238834 |
CYP3A5 | Human | chenodeoxycholic acid | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... | CTD | PMID:33819548 |
CYP3A5 | Human | CHIR 99021 | multiple interactions | EXP | | 6480464 | [4-(2-(5 more ... | CTD | PMID:34480604 |
CYP3A5 | Human | chloroethene | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Vinyl Chloride results in decreased expression of CYP3A13 mRNA | CTD | PMID:18579281 |
CYP3A5 | Human | chlorpromazine | decreases response to substance | EXP | | 6480464 | CYP3A5 protein results in decreased susceptibility to Chlorpromazine | CTD | PMID:26477383 |
CYP3A5 | Human | chlorpyrifos | increases expression | EXP | | 6480464 | Chlorpyrifos results in increased expression of CYP3A5 mRNA | CTD | PMID:16757081 and PMID:33011216 |
CYP3A5 | Human | chlorpyrifos | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Chlorpyrifos | CTD | PMID:17079358 and PMID:17110060 |
CYP3A5 | Human | chlorzoxazone | affects metabolic processing | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | CYP3A9 protein affects the metabolism of Chlorzoxazone | CTD | PMID:15879494 |
CYP3A5 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of CYP3A5 mRNA and CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] | CTD | PMID:16087946 and PMID:27392435 |
CYP3A5 | Human | cisplatin | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Cisplatin co-treated with RELB mutant form co-treated with TNF protein] results in decreased expression of CYP3A13 mRNA | CTD | PMID:23625948 |
CYP3A5 | Human | citral | multiple interactions | EXP | | 6480464 | [[CYP1A1 protein co-treated with CYP1B1 protein co-treated with CYP2B6 protein co-treated with CYP2E1 protein co-treated with CYP3A5 protein] results in increased metabolism of geraniol] which results in increased chemical synthesis of citral more ... | CTD | PMID:18824010 |
CYP3A5 | Human | clobetasol | increases expression | EXP | | 6480464 | Clobetasol results in increased expression of CYP3A5 mRNA | CTD | PMID:16882163 |
CYP3A5 | Human | clofibrate | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Clofibrate affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | clofibrate | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA] | CTD | PMID:17585979 |
CYP3A5 | Human | clofibric acid | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of CYP3A13 mRNA | CTD | PMID:17602206 |
CYP3A5 | Human | clopidogrel | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to clopidogrel | CTD | PMID:16754899 |
CYP3A5 | Human | clopidogrel | multiple interactions | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite | CTD | PMID:19170597 |
CYP3A5 | Human | clothianidin | increases expression | EXP | | 6480464 | clothianidin results in increased expression of CYP3A5 mRNA | CTD | PMID:32201337 |
CYP3A5 | Human | clothianidin | multiple interactions | EXP | | 6480464 | [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein and [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA | CTD | PMID:32201337 |
CYP3A5 | Human | clotrimazole | increases expression | EXP | | 6480464 | Clotrimazole results in increased expression of CYP3A5 protein | CTD | PMID:8632764 |
CYP3A5 | Human | clozapine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Clozapine | CTD | PMID:18809730 |
CYP3A5 | Human | Clozapine N-oxide | increases chemical synthesis | EXP | | 6480464 | CYP3A5 protein results in increased chemical synthesis of clozapine N-oxide | CTD | PMID:18809730 |
CYP3A5 | Human | cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of CYP3A5 mRNA | CTD | PMID:22941251 |
CYP3A5 | Human | copper atom | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Copper results in increased expression of CYP3A13 mRNA | CTD | PMID:22465980 |
CYP3A5 | Human | copper(0) | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Copper results in increased expression of CYP3A13 mRNA | CTD | PMID:22465980 |
CYP3A5 | Human | copper(II) sulfate | increases expression | EXP | | 6480464 | Copper Sulfate results in increased expression of CYP3A5 mRNA | CTD | PMID:19549813 |
CYP3A5 | Human | corticosterone | increases metabolic processing | ISO | Cyp3a13 (Mus musculus) | 6480464 | Corticosterone results in increased metabolism of CYP3A5 protein | CTD | PMID:20032461 |
CYP3A5 | Human | cortisol | increases expression | EXP | | 6480464 | Hydrocortisone results in increased expression of CYP3A5 mRNA | CTD | PMID:23223499 |
CYP3A5 | Human | cortisol | multiple interactions | EXP | | 6480464 | [4-(2-(5 more ... | CTD | PMID:34480604 |
CYP3A5 | Human | Cuprizon | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Cuprizone results in decreased expression of CYP3A9 mRNA | CTD | PMID:27523638 |
CYP3A5 | Human | cyazofamid | decreases expression | EXP | | 6480464 | cyazofamid results in decreased expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | cyclophosphamide | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Cyclophosphamide | CTD | PMID:16087946 |
CYP3A5 | Human | cyclophosphamide | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Cyclophosphamide results in increased expression of CYP3A13 mRNA | CTD | PMID:24819615 |
CYP3A5 | Human | cyclophosphamide | multiple interactions | EXP | | 6480464 | CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] | CTD | PMID:16087946 |
CYP3A5 | Human | cyclophosphamide | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide | CTD | PMID:16087946 |
CYP3A5 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of CYP3A5 mRNA | CTD | PMID:12673034 |
CYP3A5 | Human | cyclosporin A | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA | CTD | PMID:33819548 |
CYP3A5 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of CYP3A5 mRNA | CTD | PMID:20106945 and PMID:25562108 |
CYP3A5 | Human | cyclosporin A | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Cyclosporine and CYP3A5 protein polymorphism affects the metabolism of Cyclosporine | CTD | PMID:15450954 more ... |
CYP3A5 | Human | cypermethrin | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | cypermethrin results in increased expression of CYP3A13 mRNA | CTD | PMID:31659573 |
CYP3A5 | Human | cypermethrin | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | Sodium Selenite inhibits the reaction [cypermethrin results in increased expression of CYP3A13 mRNA] | CTD | PMID:31659573 |
CYP3A5 | Human | cyproconazole | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | cyproconazole results in increased expression of CYP3A9 protein | CTD | PMID:33150952 |
CYP3A5 | Human | D-glucose | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CYP3A13 mRNA | CTD | PMID:37567420 |
CYP3A5 | Human | dabrafenib | decreases activity | EXP | | 6480464 | dabrafenib results in decreased activity of CYP3A5 protein | CTD | PMID:34780725 |
CYP3A5 | Human | decabromodiphenyl ether | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | decabromobiphenyl ether results in increased expression of CYP3A9 mRNA | CTD | PMID:32679240 |
CYP3A5 | Human | Dechloroethylcyclophosphamide | affects chemical synthesis | EXP | | 6480464 | CYP3A5 protein affects the chemical synthesis of dechloroethylcyclophosphamide | CTD | PMID:15875221 |
CYP3A5 | Human | deguelin | affects expression | EXP | | 6480464 | deguelin affects the expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | dehydroepiandrosterone | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Dehydroepiandrosterone | CTD | PMID:15845858 |
CYP3A5 | Human | delta-tocotrienol | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to tocotrienol and delta | CTD | PMID:31102695 |
CYP3A5 | Human | delta-tocotrienol | multiple interactions | EXP | | 6480464 | tocotrienol more ... | CTD | PMID:31102695 |
CYP3A5 | Human | deoxycholic acid | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... | CTD | PMID:33819548 |
CYP3A5 | Human | dexamethasone | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Dexamethasone results in decreased expression of CYP3A9 mRNA | CTD | PMID:15102944 |
CYP3A5 | Human | dexamethasone | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Dexamethasone results in increased expression of CYP3A13 mRNA | CTD | PMID:14570766 and PMID:31678242 |
CYP3A5 | Human | dexamethasone | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Dexamethasone results in increased expression of CYP3A9 mRNA | CTD | PMID:19562681 and PMID:20888898 |
CYP3A5 | Human | dexamethasone | increases expression | EXP | | 6480464 | Dexamethasone results in increased expression of CYP3A5 mRNA | CTD | PMID:10696073 more ... |
CYP3A5 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP3A5 mRNA] and NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CYP3A5 mRNA] | CTD | PMID:12538830 |
CYP3A5 | Human | dexamethasone | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA | CTD | PMID:22341215 |
CYP3A5 | Human | dextran sulfate | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA | CTD | PMID:29950665 |
CYP3A5 | Human | dextromethorphan | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Dextromethorphan | CTD | PMID:15988119 |
CYP3A5 | Human | dextromethorphan | increases oxidation | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of Dextromethorphan | CTD | PMID:15383492 |
CYP3A5 | Human | dextromethorphan | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Dextromethorphan | CTD | PMID:15383492 |
CYP3A5 | Human | dextrorphan | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Dextrorphan | CTD | PMID:15988119 |
CYP3A5 | Human | diazinon | increases expression | EXP | | 6480464 | Diazinon results in increased expression of CYP3A5 mRNA | CTD | PMID:16757081 |
CYP3A5 | Human | diclofenac | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Diclofenac results in increased expression of CYP3A13 mRNA | CTD | PMID:26934552 |
CYP3A5 | Human | diclofenac | decreases activity | ISO | Cyp3a13 (Mus musculus) | 6480464 | Diclofenac metabolite results in decreased activity of CYP3A13 protein | CTD | PMID:28960974 |
CYP3A5 | Human | dicrotophos | decreases expression | EXP | | 6480464 | dicrotophos results in decreased expression of CYP3A5 mRNA | CTD | PMID:28302478 |
CYP3A5 | Human | diltiazem | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Diltiazem | CTD | PMID:15499178 |
CYP3A5 | Human | diltiazem | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Diltiazem and CYP3A5 protein polymorphism affects the metabolism of Diltiazem | CTD | PMID:16024008 |
CYP3A5 | Human | dimethyl sulfoxide | affects expression | EXP | | 6480464 | Dimethyl Sulfoxide affects the expression of CYP3A5 mRNA | CTD | PMID:12843640 |
CYP3A5 | Human | diosmetin | multiple interactions | EXP | | 6480464 | diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] | CTD | PMID:18191104 |
CYP3A5 | Human | disodium selenite | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | Sodium Selenite inhibits the reaction [cypermethrin results in increased expression of CYP3A13 mRNA] | CTD | PMID:31659573 |
CYP3A5 | Human | Droloxifene | decreases activity | EXP | | 6480464 | droloxifene results in decreased activity of CYP3A5 protein | CTD | PMID:12419016 |
CYP3A5 | Human | dronedarone | decreases response to substance | EXP | | 6480464 | CYP3A5 protein results in decreased susceptibility to dronedarone | CTD | PMID:29616291 |
CYP3A5 | Human | dronedarone | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of dronedarone | CTD | PMID:29616291 |
CYP3A5 | Human | dronedarone | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of Dronedarone] which results in increased abundance of N-desbutyldronedarone more ... | CTD | PMID:29616291 |
CYP3A5 | Human | elemental selenium | decreases expression | EXP | | 6480464 | Selenium results in decreased expression of CYP3A5 mRNA | CTD | PMID:19244175 |
CYP3A5 | Human | emodin | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Emodin | CTD | PMID:30672276 |
CYP3A5 | Human | endosulfan | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Endosulfan | CTD | PMID:16581944 |
CYP3A5 | Human | endosulfan | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Endosulfan results in increased expression of CYP3A9 mRNA | CTD | PMID:29391264 |
CYP3A5 | Human | enilconazole | multiple interactions | EXP | | 6480464 | [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein and [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein | CTD | PMID:32201337 |
CYP3A5 | Human | enilconazole | increases expression | EXP | | 6480464 | enilconazole results in increased expression of CYP3A5 mRNA and enilconazole results in increased expression of CYP3A5 protein | CTD | PMID:32201337 |
CYP3A5 | Human | eplerenone | increases abundance | EXP | | 6480464 | CYP3A5 protein results in increased abundance of Eplerenone metabolite | CTD | PMID:31408697 |
CYP3A5 | Human | eplerenone | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Eplerenone | CTD | PMID:31408697 |
CYP3A5 | Human | Erdafitinib | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of erdafitinib | CTD | PMID:34189909 |
CYP3A5 | Human | Erdafitinib | decreases activity | EXP | | 6480464 | erdafitinib results in decreased activity of CYP3A5 protein | CTD | PMID:34189909 |
CYP3A5 | Human | Erdafitinib | multiple interactions | EXP | | 6480464 | erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] more ... | CTD | PMID:34189909 |
CYP3A5 | Human | erythromycin A | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Erythromycin | CTD | PMID:15383492 |
CYP3A5 | Human | erythromycin estolate | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Erythromycin Estolate results in increased expression of CYP3A9 mRNA | CTD | PMID:24412560 |
CYP3A5 | Human | ethanol | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Ethanol results in increased expression of CYP3A13 mRNA | CTD | PMID:19167417 |
CYP3A5 | Human | etoposide | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to Etoposide | CTD | PMID:12969965 |
CYP3A5 | Human | etoposide | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Etoposide | CTD | PMID:8114683 |
CYP3A5 | Human | fenofibrate | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Fenofibrate co-treated with Diethylnitrosamine] results in decreased expression of CYP3A13 mRNA | CTD | PMID:18253720 |
CYP3A5 | Human | fenpyroximate | increases expression | EXP | | 6480464 | fenpyroximate results in increased expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | fenthion | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Fenthion | CTD | PMID:17110060 |
CYP3A5 | Human | fimasartan | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of fimasartan | CTD | PMID:29596975 |
CYP3A5 | Human | fimasartan | increases oxidation | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of fimasartan | CTD | PMID:29596975 |
CYP3A5 | Human | fipronil | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | fipronil results in increased expression of CYP3A9 mRNA | CTD | PMID:23962444 |
CYP3A5 | Human | fipronil | increases expression | EXP | | 6480464 | fipronil results in increased expression of CYP3A5 mRNA | CTD | PMID:17084830 and PMID:27091632 |
CYP3A5 | Human | fipronil | multiple interactions | EXP | | 6480464 | [fipronil co-treated with DEET] results in increased expression of CYP3A5 mRNA | CTD | PMID:27091632 |
CYP3A5 | Human | flavonol | increases expression | EXP | | 6480464 | 3-hydroxyflavone results in increased expression of CYP3A5 mRNA | CTD | PMID:26238175 |
CYP3A5 | Human | fluconazole | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Fluconazole results in increased expression of CYP3A13 mRNA | CTD | PMID:16643972 |
CYP3A5 | Human | flunisolide | multiple interactions | EXP | | 6480464 | Ketoconazole inhibits the reaction [flunisolide results in increased expression of CYP3A5 mRNA] | CTD | PMID:24555085 |
CYP3A5 | Human | flunisolide | increases expression | EXP | | 6480464 | flunisolide results in increased expression of CYP3A5 mRNA | CTD | PMID:24555085 |
CYP3A5 | Human | flunitrazepam | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Flunitrazepam | CTD | PMID:15383492 |
CYP3A5 | Human | fluoxetine | multiple interactions | EXP | | 6480464 | Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] | CTD | PMID:12584149 |
CYP3A5 | Human | fluticasone | decreases activity | EXP | | 6480464 | Fluticasone results in decreased activity of CYP3A5 protein | CTD | PMID:20707410 |
CYP3A5 | Human | fluticasone | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Fluticasone | CTD | PMID:20707410 |
CYP3A5 | Human | fluticasone | affects response to substance | EXP | | 6480464 | CYP3A5 protein affects the susceptibility to Fluticasone | CTD | PMID:20707410 |
CYP3A5 | Human | fluticasone | multiple interactions | EXP | | 6480464 | Ketoconazole inhibits the reaction [Fluticasone results in increased expression of CYP3A5 mRNA] | CTD | PMID:24555085 |
CYP3A5 | Human | fluticasone | increases expression | EXP | | 6480464 | Fluticasone results in increased expression of CYP3A5 mRNA | CTD | PMID:24555085 |
CYP3A5 | Human | fluvoxamine | multiple interactions | EXP | | 6480464 | Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] | CTD | PMID:12584149 |
CYP3A5 | Human | folic acid | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of CYP3A13 mRNA | CTD | PMID:25629700 |
CYP3A5 | Human | fructose | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CYP3A13 mRNA | CTD | PMID:37567420 |
CYP3A5 | Human | fumonisin B1 | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | fumonisin B1 results in decreased expression of CYP3A13 mRNA | CTD | PMID:16221962 |
CYP3A5 | Human | gallocatechin | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA | CTD | PMID:25663641 |
CYP3A5 | Human | gefitinib | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of gefitinib | CTD | PMID:15788367 |
CYP3A5 | Human | Gelsemine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of gelsemine | CTD | PMID:34627953 |
CYP3A5 | Human | genistein | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Genistein co-treated with Methoxychlor] results in increased expression of CYP3A9 mRNA | CTD | PMID:21782745 |
CYP3A5 | Human | genistein | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Genistein results in decreased expression of CYP3A13 mRNA | CTD | PMID:32186404 |
CYP3A5 | Human | geranial | multiple interactions | EXP | | 6480464 | [[CYP1A1 protein co-treated with CYP1B1 protein co-treated with CYP2B6 protein co-treated with CYP2E1 protein co-treated with CYP3A5 protein] results in increased metabolism of geraniol] which results in increased chemical synthesis of citral more ... | CTD | PMID:18824010 |
CYP3A5 | Human | geraniol | multiple interactions | EXP | | 6480464 | [[CYP1A1 protein co-treated with CYP1B1 protein co-treated with CYP2B6 protein co-treated with CYP2E1 protein co-treated with CYP3A5 protein] results in increased metabolism of geraniol] which results in increased chemical synthesis of citral more ... | CTD | PMID:18824010 |
CYP3A5 | Human | geraniol | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of geraniol | CTD | PMID:18824010 |
CYP3A5 | Human | glucose | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CYP3A13 mRNA | CTD | PMID:37567420 |
CYP3A5 | Human | glutathione | multiple interactions | EXP | | 6480464 | [CYP3A5 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac more ... | CTD | PMID:24246759 and PMID:26302866 |
CYP3A5 | Human | glycochenodeoxycholic acid | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... | CTD | PMID:33819548 |
CYP3A5 | Human | glycocholic acid | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... | CTD | PMID:33819548 |
CYP3A5 | Human | glycodeoxycholic acid | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... | CTD | PMID:33819548 |
CYP3A5 | Human | haloperidol | multiple interactions | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol more ... | CTD | PMID:12584149 |
CYP3A5 | Human | helenalin | decreases activity | EXP | | 6480464 | helenalin results in decreased activity of CYP3A5 protein | CTD | PMID:34989853 |
CYP3A5 | Human | helenalin | increases oxidation | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of helenalin | CTD | PMID:34989853 |
CYP3A5 | Human | Heliotrine | decreases expression | EXP | | 6480464 | heliotrine results in decreased expression of CYP3A5 mRNA | CTD | PMID:26100227 |
CYP3A5 | Human | Hexachloro-1,3-butadiene | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of hexachlorobutadiene | CTD | PMID:8555406 |
CYP3A5 | Human | hydroquinone | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of bisphenol A] which results in increased chemical synthesis of hydroquinone | CTD | PMID:21402134 |
CYP3A5 | Human | Hypaconitine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of hypaconitine | CTD | PMID:21550385 |
CYP3A5 | Human | hyperforin | increases expression | EXP | | 6480464 | hyperforin results in increased expression of CYP3A5 mRNA | CTD | PMID:24259679 |
CYP3A5 | Human | Icaritin | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of icaritin | CTD | PMID:30938510 |
CYP3A5 | Human | ifosfamide | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Ifosfamide | CTD | PMID:15875221 |
CYP3A5 | Human | ifosfamide | decreases ethylation | EXP | | 6480464 | CYP3A5 protein results in decreased ethylation of Ifosfamide | CTD | PMID:15821045 |
CYP3A5 | Human | indole-3-methanol | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | indole-3-carbinol affects the expression of CYP3A9 mRNA | CTD | PMID:21396975 |
CYP3A5 | Human | indometacin | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Indomethacin results in increased expression of CYP3A9 mRNA | CTD | PMID:18299717 |
CYP3A5 | Human | inulin | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of CYP3A13 mRNA | CTD | PMID:36331819 |
CYP3A5 | Human | irinotecan | multiple interactions | EXP | | 6480464 | [selenomethylselenocysteine co-treated with Irinotecan] results in increased expression of CYP3A5 | CTD | PMID:15897249 |
CYP3A5 | Human | ketoconazole | multiple interactions | EXP | | 6480464 | CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus] more ... | CTD | PMID:15731592 more ... |
CYP3A5 | Human | ketoconazole | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to Ketoconazole | CTD | PMID:31102695 |
CYP3A5 | Human | ketoconazole | decreases activity | EXP | | 6480464 | Ketoconazole results in decreased activity of CYP3A5 protein | CTD | PMID:15557344 more ... |
CYP3A5 | Human | L-ascorbic acid | multiple interactions | EXP | | 6480464 | [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA | CTD | PMID:34480604 |
CYP3A5 | Human | L-ascorbic acid 2-phosphate | multiple interactions | EXP | | 6480464 | [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA | CTD | PMID:34480604 |
CYP3A5 | Human | L-ethionine | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Ethionine affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | lansoprazole | multiple interactions | EXP | | 6480464 | CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] | CTD | PMID:17377957 |
CYP3A5 | Human | lapatinib | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Lapatinib | CTD | PMID:26958860 and PMID:37788138 |
CYP3A5 | Human | lapatinib | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein and CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein] | CTD | PMID:26958860 and PMID:37788138 |
CYP3A5 | Human | Lasiocarpine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of lasiocarpine | CTD | PMID:31103741 |
CYP3A5 | Human | lead diacetate | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | lead acetate results in increased expression of CYP3A9 mRNA | CTD | PMID:22641619 |
CYP3A5 | Human | lidocaine | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Lidocaine | CTD | PMID:15383492 |
CYP3A5 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 |
CYP3A5 | Human | lipopolysaccharide | increases expression | EXP | | 6480464 | Lipopolysaccharides results in increased expression of CYP3A5 mRNA | CTD | PMID:35811015 |
CYP3A5 | Human | lithocholic acid | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Lithocholic Acid results in increased expression of CYP3A9 mRNA | CTD | PMID:20888898 |
CYP3A5 | Human | lithocholic acid | increases oxidation | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of Lithocholic Acid | CTD | PMID:31102695 |
CYP3A5 | Human | lithocholic acid | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased oxidation of Lithocholic Acid] which results in increased chemical synthesis of 3-ketocholanoic acid more ... | CTD | PMID:31102695 |
CYP3A5 | Human | luteolin | multiple interactions | EXP | | 6480464 | Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] | CTD | PMID:18191104 |
CYP3A5 | Human | lycopene | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | Lycopene inhibits the reaction [Atrazine results in increased expression of CYP3A13 mRNA] | CTD | PMID:36216167 |
CYP3A5 | Human | malathion | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Malathion | CTD | PMID:17110060 |
CYP3A5 | Human | malathion | increases expression | EXP | | 6480464 | Malathion results in increased expression of CYP3A5 mRNA | CTD | PMID:37047231 |
CYP3A5 | Human | Meclizine | multiple interactions | EXP | | 6480464 | Meclizine inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone] and Meclizine inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone] | CTD | PMID:26239802 |
CYP3A5 | Human | mercury dichloride | increases expression | EXP | | 6480464 | Mercuric Chloride results in increased expression of CYP3A5 mRNA | CTD | PMID:37172713 |
CYP3A5 | Human | methoxychlor | decreases methylation | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | CYP3A5 protein results in decreased methylation of Methoxychlor | CTD | PMID:12433799 |
CYP3A5 | Human | methoxychlor | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Methoxychlor results in increased expression of CYP3A9 mRNA | CTD | PMID:21782745 |
CYP3A5 | Human | methoxychlor | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Genistein co-treated with Methoxychlor] results in increased expression of CYP3A9 mRNA | CTD | PMID:21782745 |
CYP3A5 | Human | midazolam | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Midazolam | CTD | PMID:26958860 |
CYP3A5 | Human | midazolam | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam more ... | CTD | PMID:19557931 and PMID:34189909 |
CYP3A5 | Human | midazolam | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Midazolam | CTD | PMID:15383492 more ... |
CYP3A5 | Human | midazolam | affects metabolic processing | EXP | | 6480464 | CYP3A5 gene polymorphism affects the metabolism of Midazolam and CYP3A5 protein affects the metabolism of Midazolam | CTD | PMID:15801540 more ... |
CYP3A5 | Human | midazolam | affects metabolic processing | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | CYP3A5 protein affects the metabolism of Midazolam | CTD | PMID:15801540 |
CYP3A5 | Human | mifepristone | multiple interactions | EXP | | 6480464 | Mifepristone inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] more ... | CTD | PMID:12538830 |
CYP3A5 | Human | monosodium L-glutamate | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Sodium Glutamate results in decreased expression of CYP3A9 mRNA | CTD | PMID:20928830 |
CYP3A5 | Human | monosodium L-glutamate | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA and [Sodium Glutamate co-treated with Tea] affects the expression of CYP3A13 mRNA | CTD | PMID:25663641 |
CYP3A5 | Human | mycophenolic acid | increases methylation | EXP | | 6480464 | CYP3A5 protein results in increased methylation of Mycophenolic Acid | CTD | PMID:15570183 |
CYP3A5 | Human | N,N-diethyl-m-toluamide | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of DEET | CTD | PMID:11854147 |
CYP3A5 | Human | N,N-diethyl-m-toluamide | multiple interactions | EXP | | 6480464 | [fipronil co-treated with DEET] results in increased expression of CYP3A5 mRNA | CTD | PMID:27091632 |
CYP3A5 | Human | N,N-diethyl-m-toluamide | increases expression | EXP | | 6480464 | DEET results in increased expression of CYP3A5 mRNA | CTD | PMID:27091632 |
CYP3A5 | Human | N-desmethylclozapine | increases chemical synthesis | EXP | | 6480464 | CYP3A5 protein results in increased chemical synthesis of norclozapine | CTD | PMID:18809730 |
CYP3A5 | Human | N-Desmethyltamoxifen | decreases activity | EXP | | 6480464 | N-desmethyltamoxifen results in decreased activity of CYP3A5 protein | CTD | PMID:12419016 |
CYP3A5 | Human | N-Desmethyltamoxifen | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of N-desmethyltamoxifen] which results in increased abundance of 1-(4-hydroxyphenyl)-1 and 2-diphenyl-1-butene | CTD | PMID:29285606 |
CYP3A5 | Human | N-Desmethyltamoxifen | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of N-desmethyltamoxifen | CTD | PMID:29285606 |
CYP3A5 | Human | N-methyl-4-phenylpyridinium | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of CYP3A9 mRNA | CTD | PMID:28801915 |
CYP3A5 | Human | N-nitrosodiethylamine | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of CYP3A13 mRNA more ... | CTD | PMID:17602206 more ... |
CYP3A5 | Human | N-nitrosodiethylamine | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | MET protein inhibits the reaction [Diethylnitrosamine results in increased expression of CYP3A13 mRNA] | CTD | PMID:17942915 |
CYP3A5 | Human | N-nitrosodiethylamine | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Diethylnitrosamine results in increased expression of CYP3A13 mRNA | CTD | PMID:17942915 |
CYP3A5 | Human | N-nitrosodiethylamine | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Diethylnitrosamine results in decreased expression of CYP3A13 mRNA | CTD | PMID:19638242 |
CYP3A5 | Human | N-nitrosodimethylamine | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Dimethylnitrosamine results in decreased expression of CYP3A9 mRNA | CTD | PMID:25380136 |
CYP3A5 | Human | N-nitrosodimethylamine | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Dimethylnitrosamine results in increased expression of CYP3A13 mRNA | CTD | PMID:17072980 |
CYP3A5 | Human | N-Vinyl-2-pyrrolidone | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP3A9 mRNA | CTD | PMID:22037397 |
CYP3A5 | Human | naphthalene | increases expression | EXP | | 6480464 | naphthalene results in increased expression of CYP3A5 mRNA | CTD | PMID:20500019 |
CYP3A5 | Human | nefazodone | multiple interactions | EXP | | 6480464 | nefazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] | CTD | PMID:12584149 |
CYP3A5 | Human | nefazodone | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | nefazodone results in increased expression of CYP3A9 mRNA | CTD | PMID:24136188 |
CYP3A5 | Human | nelfinavir | decreases activity | EXP | | 6480464 | Nelfinavir results in decreased activity of CYP3A5 protein | CTD | PMID:15523003 |
CYP3A5 | Human | nevirapine | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Nevirapine results in increased expression of CYP3A9 mRNA | CTD | PMID:23947594 |
CYP3A5 | Human | nickel atom | decreases expression | EXP | | 6480464 | Nickel results in decreased expression of CYP3A5 mRNA | CTD | PMID:24768652 and PMID:25583101 |
CYP3A5 | Human | nimesulide | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | nimesulide results in increased expression of CYP3A9 mRNA | CTD | PMID:24136188 |
CYP3A5 | Human | Norfluoxetine | multiple interactions | EXP | | 6480464 | norfluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] | CTD | PMID:12584149 |
CYP3A5 | Human | nortriptyline | increases metabolic processing | EXP | | 6480464 | Nortriptyline results in increased metabolism of CYP3A5 protein | CTD | PMID:18359012 |
CYP3A5 | Human | norverapamil | decreases activity | EXP | | 6480464 | norverapamil results in decreased activity of CYP3A5 protein | CTD | PMID:15689501 |
CYP3A5 | Human | obeticholic acid | decreases expression | EXP | | 6480464 | obeticholic acid results in decreased expression of CYP3A5 mRNA | CTD | PMID:27939613 |
CYP3A5 | Human | ochratoxin A | increases response to substance | EXP | | 6480464 | CYP3A5 protein results in increased susceptibility to ochratoxin A | CTD | PMID:11189750 |
CYP3A5 | Human | ochratoxin A | decreases expression | EXP | | 6480464 | ochratoxin A results in decreased expression of CYP3A5 mRNA | CTD | PMID:26505656 |
CYP3A5 | Human | ochratoxin A | increases expression | EXP | | 6480464 | ochratoxin A results in increased expression of CYP3A5 mRNA | CTD | PMID:21834667 |
CYP3A5 | Human | okadaic acid | multiple interactions | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of and results in increased hydroxylation of and results in decreased susceptibility to Okadaic Acid | CTD | PMID:26374342 |
CYP3A5 | Human | omeprazole | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Omeprazole affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | omeprazole | increases expression | EXP | | 6480464 | Omeprazole results in increased expression of CYP3A5 mRNA | CTD | PMID:19118567 |
CYP3A5 | Human | ozone | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of CYP3A13 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in increased expression of CYP3A13 mRNA | CTD | PMID:34911549 |
CYP3A5 | Human | paracetamol | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Acetaminophen affects the expression of CYP3A13 mRNA | CTD | PMID:17366322 |
CYP3A5 | Human | paracetamol | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA] | CTD | PMID:17585979 |
CYP3A5 | Human | paracetamol | increases activity | ISO | Cyp3a13 (Mus musculus) | 6480464 | Acetaminophen results in increased activity of CYP3A5 protein | CTD | PMID:35948136 |
CYP3A5 | Human | paracetamol | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Acetaminophen affects the expression of CYP3A13 mRNA | CTD | PMID:17562736 |
CYP3A5 | Human | paracetamol | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA | CTD | PMID:33819548 |
CYP3A5 | Human | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of CYP3A5 mRNA | CTD | PMID:29067470 |
CYP3A5 | Human | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of CYP3A5 mRNA | CTD | PMID:26497421 |
CYP3A5 | Human | paraoxon | multiple interactions | EXP | | 6480464 | Paraoxon inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] | CTD | PMID:24555085 |
CYP3A5 | Human | parathion | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Parathion | CTD | PMID:12669189 more ... |
CYP3A5 | Human | PD 0325901 | increases expression | EXP | | 6480464 | mirdametinib results in increased expression of CYP3A5 mRNA | CTD | PMID:24819614 |
CYP3A5 | Human | perfluorohexanesulfonic acid | increases expression | EXP | | 6480464 | perfluorohexanesulfonic acid results in increased expression of CYP3A5 mRNA | CTD | PMID:23567314 |
CYP3A5 | Human | perfluorooctane-1-sulfonic acid | decreases expression | EXP | | 6480464 | perfluorooctane sulfonic acid results in decreased expression of CYP3A5 mRNA | CTD | PMID:27153767 |
CYP3A5 | Human | perfluorooctane-1-sulfonic acid | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | perfluorooctane sulfonic acid results in increased expression of CYP3A13 mRNA | CTD | PMID:20936131 |
CYP3A5 | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of CYP3A13 mRNA more ... | CTD | PMID:36331819 |
CYP3A5 | Human | perfluorooctanoic acid | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | perfluorooctanoic acid affects the expression of CYP3A13 mRNA | CTD | PMID:18281256 |
CYP3A5 | Human | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of CYP3A5 mRNA | CTD | PMID:37302725 |
CYP3A5 | Human | perfluorooctanoic acid | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | perfluorooctanoic acid results in increased expression of CYP3A13 mRNA | CTD | PMID:25949234 |
CYP3A5 | Human | permethrin | increases expression | EXP | | 6480464 | Permethrin results in increased expression of CYP3A5 mRNA | CTD | PMID:19326768 |
CYP3A5 | Human | phencyclidine | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Phencyclidine | CTD | PMID:16782764 |
CYP3A5 | Human | phenethyl isothiocyanate | decreases expression | EXP | | 6480464 | phenethyl isothiocyanate results in decreased expression of CYP3A5 mRNA | CTD | PMID:20442190 |
CYP3A5 | Human | phenobarbital | increases expression | EXP | | 6480464 | Phenobarbital results in increased expression of CYP3A5 mRNA and Phenobarbital results in increased expression of CYP3A5 protein | CTD | PMID:10696073 more ... |
CYP3A5 | Human | phenobarbital | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Phenobarbital affects the expression of CYP3A13 mRNA | CTD | PMID:23091169 |
CYP3A5 | Human | phenobarbital | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Phenobarbital results in increased expression of CYP3A13 mRNA | CTD | PMID:19270015 and PMID:19850644 |
CYP3A5 | Human | phenobarbital | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Phenobarbital results in increased expression of CYP3A9 mRNA | CTD | PMID:19162173 more ... |
CYP3A5 | Human | phenobarbital | affects expression | EXP | | 6480464 | Phenobarbital affects the expression of CYP3A5 mRNA | CTD | PMID:19159669 |
CYP3A5 | Human | phenytoin | increases expression | EXP | | 6480464 | Phenytoin results in increased expression of CYP3A5 mRNA | CTD | PMID:12673034 |
CYP3A5 | Human | phenytoin | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Phenytoin results in increased expression of CYP3A13 mRNA | CTD | PMID:19903449 |
CYP3A5 | Human | physostigmine | multiple interactions | EXP | | 6480464 | Physostigmine inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] | CTD | PMID:24555085 |
CYP3A5 | Human | picoxystrobin | affects expression | EXP | | 6480464 | picoxystrobin affects the expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | pirinixic acid | multiple interactions | EXP | | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CYP3A5 mRNA | CTD | PMID:19710929 |
CYP3A5 | Human | pirinixic acid | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of CYP3A13 mRNA | CTD | PMID:18445702 |
CYP3A5 | Human | pirinixic acid | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CYP3A13 mRNA | CTD | PMID:19710929 |
CYP3A5 | Human | pirinixic acid | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of CYP3A13 mRNA | CTD | PMID:19850644 |
CYP3A5 | Human | pirinixic acid | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | pirinixic acid results in decreased expression of CYP3A9 mRNA | CTD | PMID:19162173 more ... |
CYP3A5 | Human | pirinixic acid | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | pirinixic acid affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | pregnenolone 16alpha-carbonitrile | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Pregnenolone Carbonitrile results in increased expression of CYP3A9 mRNA | CTD | PMID:15596064 more ... |
CYP3A5 | Human | pregnenolone 16alpha-carbonitrile | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Pregnenolone Carbonitrile results in increased expression of CYP3A13 mRNA | CTD | PMID:28903501 |
CYP3A5 | Human | prochloraz | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | prochloraz results in increased expression of CYP3A9 protein | CTD | PMID:33150952 |
CYP3A5 | Human | progesterone | increases expression | EXP | | 6480464 | Progesterone results in increased expression of CYP3A5 mRNA | CTD | PMID:22837389 |
CYP3A5 | Human | pyrazinecarboxamide | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Pyrazinamide results in decreased expression of CYP3A9 mRNA | CTD | PMID:22431067 |
CYP3A5 | Human | quercetin | increases expression | EXP | | 6480464 | Quercetin results in increased expression of CYP3A5 mRNA | CTD | PMID:26238175 |
CYP3A5 | Human | quercetin | affects expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Quercetin affects the expression of CYP3A13 mRNA | CTD | PMID:19270413 |
CYP3A5 | Human | quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of CYP3A5 mRNA | CTD | PMID:21632981 |
CYP3A5 | Human | quinacrine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Quinacrine | CTD | PMID:16581945 |
CYP3A5 | Human | rabeprazole | multiple interactions | EXP | | 6480464 | CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole] | CTD | PMID:17377957 |
CYP3A5 | Human | reactive oxygen species | multiple interactions | EXP | | 6480464 | CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species] | CTD | PMID:26302866 |
CYP3A5 | Human | Rebamipide | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | rebamipide results in increased expression of CYP3A9 mRNA | CTD | PMID:18299717 |
CYP3A5 | Human | reserpine | increases expression | EXP | | 6480464 | Reserpine results in increased expression of CYP3A5 protein | CTD | PMID:8632764 |
CYP3A5 | Human | riddelliine | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | riddelliine results in increased expression of CYP3A9 mRNA | CTD | PMID:18047727 |
CYP3A5 | Human | rifampicin | increases expression | EXP | | 6480464 | Rifampin results in increased expression of CYP3A5 mRNA | CTD | PMID:12040753 more ... |
CYP3A5 | Human | risperidone | affects abundance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the abundance of Risperidone and CYP3A5 protein affects the abundance of Risperidone | CTD | PMID:20332423 |
CYP3A5 | Human | risperidone | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Risperidone | CTD | PMID:18708991 |
CYP3A5 | Human | ritonavir | decreases activity | EXP | | 6480464 | Ritonavir results in decreased activity of CYP3A5 protein | CTD | PMID:15523003 |
CYP3A5 | Human | rivaroxaban | multiple interactions | EXP | | 6480464 | erdafitinib inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Rivaroxaban] | CTD | PMID:34189909 |
CYP3A5 | Human | rivaroxaban | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Rivaroxaban | CTD | PMID:34189909 |
CYP3A5 | Human | romidepsin | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of romidepsin | CTD | PMID:15635176 |
CYP3A5 | Human | rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 |
CYP3A5 | Human | Salinomycin | increases expression | EXP | | 6480464 | salinomycin results in increased expression of CYP3A5 mRNA | CTD | PMID:34806536 |
CYP3A5 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with EGF protein co-treated with FGF2 protein] results in increased expression of CYP3A5 mRNA | CTD | PMID:34480604 |
CYP3A5 | Human | Se-methyl-L-selenocysteine | multiple interactions | EXP | | 6480464 | [selenomethylselenocysteine co-treated with irinotecan] results in increased expression of CYP3A5 | CTD | PMID:15897249 |
CYP3A5 | Human | Se-methylselenocysteine | multiple interactions | EXP | | 6480464 | [selenomethylselenocysteine co-treated with irinotecan] results in increased expression of CYP3A5 | CTD | PMID:15897249 |
CYP3A5 | Human | selenium atom | decreases expression | EXP | | 6480464 | Selenium results in decreased expression of CYP3A5 mRNA | CTD | PMID:19244175 |
CYP3A5 | Human | senecionine | decreases expression | EXP | | 6480464 | senecionine results in decreased expression of CYP3A5 mRNA | CTD | PMID:26100227 |
CYP3A5 | Human | Senkirkine | decreases expression | EXP | | 6480464 | senkirkine results in decreased expression of CYP3A5 mRNA | CTD | PMID:26100227 |
CYP3A5 | Human | silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide analog results in decreased expression of CYP3A5 mRNA | CTD | PMID:25895662 |
CYP3A5 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of CYP3A5 mRNA | CTD | PMID:23806026 |
CYP3A5 | Human | simvastatin | affects response to substance | EXP | | 6480464 | CYP3A5 polymorphism affects the susceptibility to Simvastatin | CTD | PMID:17192506 |
CYP3A5 | Human | sodium arsenate | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA | CTD | PMID:32525701 |
CYP3A5 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of CYP3A5 mRNA | CTD | PMID:29301061 |
CYP3A5 | Human | sodium arsenite | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of CYP3A13 mRNA and sodium arsenite results in decreased expression of CYP3A5 mRNA | CTD | PMID:11353140 and PMID:31532247 |
CYP3A5 | Human | sodium dichromate | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | sodium bichromate results in decreased expression of CYP3A9 mRNA | CTD | PMID:25993096 |
CYP3A5 | Human | sorafenib | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein polymorphism affects the metabolism of Sorafenib | CTD | PMID:35099304 |
CYP3A5 | Human | sulfaphenazole | multiple interactions | EXP | | 6480464 | Sulfaphenazole inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone] | CTD | PMID:31102695 |
CYP3A5 | Human | tacrolimus hydrate | multiple interactions | EXP | | 6480464 | CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] more ... | CTD | PMID:17377957 and PMID:19384264 |
CYP3A5 | Human | tacrolimus hydrate | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Tacrolimus | CTD | PMID:15951320 |
CYP3A5 | Human | tacrolimus hydrate | affects metabolic processing | EXP | | 6480464 | CYP3A5 gene polymorphism affects the metabolism of Tacrolimus more ... | CTD | PMID:15502717 more ... |
CYP3A5 | Human | tacrolimus hydrate | affects response to substance | EXP | | 6480464 | CYP3A5 gene affects the susceptibility to Tacrolimus and CYP3A5 polymorphism affects the susceptibility to Tacrolimus | CTD | PMID:15723604 and PMID:36931438 |
CYP3A5 | Human | tamarixetin | increases expression | EXP | | 6480464 | tamarixetin results in increased expression of CYP3A5 mRNA | CTD | PMID:26238175 |
CYP3A5 | Human | tamoxifen | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Tamoxifen and CYP3A5 protein polymorphism affects the metabolism of Tamoxifen | CTD | PMID:15596297 |
CYP3A5 | Human | tamoxifen | decreases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Tamoxifen results in decreased expression of CYP3A13 mRNA | CTD | PMID:25123088 |
CYP3A5 | Human | tamoxifen | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Tamoxifen | CTD | PMID:29285606 |
CYP3A5 | Human | tamoxifen | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased metabolism of Tamoxifen] which results in increased abundance of 1-(4-hydroxyphenyl)-1 and 2-diphenyl-1-butene | CTD | PMID:29285606 |
CYP3A5 | Human | tamoxifen | decreases activity | EXP | | 6480464 | Tamoxifen results in decreased activity of CYP3A5 protein | CTD | PMID:12419016 |
CYP3A5 | Human | tanespimycin | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of tanespimycin | CTD | PMID:15718306 |
CYP3A5 | Human | tartrazine | multiple interactions | EXP | | 6480464 | [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA | CTD | PMID:33819548 |
CYP3A5 | Human | tebufenpyrad | increases expression | EXP | | 6480464 | 4-chloro-N-((4-(1 and 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in increased expression of CYP3A5 mRNA | CTD | PMID:34642769 |
CYP3A5 | Human | teniposide | decreases methylation | EXP | | 6480464 | CYP3A5 protein results in decreased methylation of Teniposide | CTD | PMID:8114683 |
CYP3A5 | Human | Terfenadine | affects metabolic processing | EXP | | 6480464 | CYP3A5 protein affects the metabolism of Terfenadine | CTD | PMID:15383492 |
CYP3A5 | Human | testosterone | increases expression | EXP | | 6480464 | Testosterone results in increased expression of CYP3A5 mRNA | CTD | PMID:21592394 |
CYP3A5 | Human | testosterone | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA | CTD | PMID:32741896 |
CYP3A5 | Human | testosterone | decreases expression | EXP | | 6480464 | Testosterone results in decreased expression of CYP3A5 mRNA | CTD | PMID:33359661 |
CYP3A5 | Human | testosterone | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Testosterone | CTD | PMID:15383492 more ... |
CYP3A5 | Human | testosterone | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone more ... | CTD | PMID:21592394 more ... |
CYP3A5 | Human | testosterone | affects metabolic processing | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | CYP3A9 protein affects the metabolism of Testosterone | CTD | PMID:15879494 |
CYP3A5 | Human | tetrachloroethene | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Tetrachloroethylene results in increased expression of CYP3A13 mRNA | CTD | PMID:28973375 |
CYP3A5 | Human | tetrachloromethane | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in decreased expression of CYP3A9 mRNA | CTD | PMID:31150632 |
CYP3A5 | Human | tetrachloromethane | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of CYP3A13 mRNA | CTD | PMID:27339419 and PMID:31919559 |
CYP3A5 | Human | tetrodotoxin | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA | CTD | PMID:22341215 |
CYP3A5 | Human | thalidomide | multiple interactions | EXP | | 6480464 | [CYP3A5 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide | CTD | PMID:20443640 |
CYP3A5 | Human | thalidomide | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Thalidomide | CTD | PMID:28745489 |
CYP3A5 | Human | thalidomide | increases expression | EXP | | 6480464 | Thalidomide results in increased expression of CYP3A5 mRNA | CTD | PMID:28496040 |
CYP3A5 | Human | thalidomide | increases hydroxylation | EXP | | 6480464 | CYP3A5 protein results in increased hydroxylation of Thalidomide | CTD | PMID:20443640 |
CYP3A5 | Human | thiacloprid | increases expression | EXP | | 6480464 | thiacloprid results in increased expression of CYP3A5 mRNA | CTD | PMID:32201337 |
CYP3A5 | Human | thiacloprid | multiple interactions | EXP | | 6480464 | [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein and [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA | CTD | PMID:32201337 |
CYP3A5 | Human | thioacetamide | affects expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Thioacetamide affects the expression of CYP3A9 mRNA | CTD | PMID:19483382 |
CYP3A5 | Human | thioacetamide | multiple interactions | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of CYP3A13 mRNA | CTD | PMID:28943392 |
CYP3A5 | Human | thioacetamide | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Thioacetamide results in decreased expression of CYP3A9 mRNA | CTD | PMID:23411599 and PMID:34492290 |
CYP3A5 | Human | Thiotepa | affects export | EXP | | 6480464 | CYP3A5 gene SNP affects the export of Thiotepa | CTD | PMID:19076156 |
CYP3A5 | Human | Thiotepa | affects response to substance | EXP | | 6480464 | CYP3A5 protein affects the susceptibility to Thiotepa | CTD | PMID:19076156 |
CYP3A5 | Human | ticlopidine | multiple interactions | EXP | | 6480464 | CYP3A5 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite | CTD | PMID:19170597 |
CYP3A5 | Human | titanium dioxide | multiple interactions | ISO | Cyp3a13 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA | CTD | PMID:29950665 |
CYP3A5 | Human | trabectedin | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | trabectedin results in decreased expression of CYP3A13 mRNA | CTD | PMID:12154027 |
CYP3A5 | Human | trazodone | multiple interactions | EXP | | 6480464 | Trazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] | CTD | PMID:12584149 |
CYP3A5 | Human | triadimefon | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | triadimefon results in increased expression of CYP3A13 mRNA | CTD | PMID:19010342 |
CYP3A5 | Human | triamcinolone acetonide | multiple interactions | EXP | | 6480464 | Ketoconazole inhibits the reaction [Triamcinolone Acetonide results in increased expression of CYP3A5 mRNA] | CTD | PMID:24555085 |
CYP3A5 | Human | triamcinolone acetonide | increases expression | EXP | | 6480464 | Triamcinolone Acetonide results in increased expression of CYP3A5 mRNA | CTD | PMID:24555085 |
CYP3A5 | Human | triclosan | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Triclosan results in increased expression of CYP3A9 mRNA | CTD | PMID:22659317 |
CYP3A5 | Human | triclosan | increases expression | EXP | | 6480464 | Triclosan results in increased expression of CYP3A5 mRNA | CTD | PMID:29849464 |
CYP3A5 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of CYP3A5 mRNA | CTD | PMID:37042841 |
CYP3A5 | Human | triptonide | increases expression | ISO | Cyp3a13 (Mus musculus) | 6480464 | triptonide results in increased expression of CYP3A13 mRNA | CTD | PMID:33045310 |
CYP3A5 | Human | Tris(1-aziridinyl)phosphine oxide | affects export | EXP | | 6480464 | CYP3A5 gene SNP affects the export of Triethylenephosphoramide | CTD | PMID:19076156 |
CYP3A5 | Human | Tris(1-aziridinyl)phosphine oxide | affects response to substance | EXP | | 6480464 | CYP3A5 protein affects the susceptibility to Triethylenephosphoramide | CTD | PMID:19076156 |
CYP3A5 | Human | troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of CYP3A5 | CTD | PMID:15618651 |
CYP3A5 | Human | troglitazone | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of troglitazone | CTD | PMID:19356091 |
CYP3A5 | Human | troleandomycin | decreases activity | EXP | | 6480464 | Troleandomycin results in decreased activity of CYP3A5 protein | CTD | PMID:15557344 |
CYP3A5 | Human | troleandomycin | multiple interactions | EXP | | 6480464 | Troleandomycin inhibits the reaction [CYP3A5 protein affects the metabolism of Alfentanil] | CTD | PMID:15731592 |
CYP3A5 | Human | undecane | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | undecane results in decreased expression of CYP3A13 protein | CTD | PMID:17337753 |
CYP3A5 | Human | valdecoxib | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | valdecoxib results in increased expression of CYP3A9 mRNA | CTD | PMID:24136188 |
CYP3A5 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of CYP3A5 mRNA | CTD | PMID:29154799 |
CYP3A5 | Human | valsartan | affects response to substance | EXP | | 6480464 | CYP3A5 gene affects the susceptibility to Valsartan | CTD | PMID:22149319 |
CYP3A5 | Human | verapamil | decreases activity | EXP | | 6480464 | Verapamil results in decreased activity of CYP3A5 protein | CTD | PMID:15689501 |
CYP3A5 | Human | verapamil | decreases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Verapamil results in decreased expression of CYP3A9 mRNA | CTD | PMID:17973928 |
CYP3A5 | Human | vincristine | multiple interactions | EXP | | 6480464 | [CYP3A5 gene polymorphism results in increased activity of CYP3A5 protein] which results in increased metabolism of Vincristine | CTD | PMID:21225912 |
CYP3A5 | Human | vincristine | increases metabolic processing | EXP | | 6480464 | CYP3A5 protein results in increased metabolism of Vincristine | CTD | PMID:21225912 |
CYP3A5 | Human | vitamin E | decreases expression | EXP | | 6480464 | Vitamin E results in decreased expression of CYP3A5 mRNA | CTD | PMID:19244175 |
CYP3A5 | Human | warfarin | affects response to substance | EXP | | 6480464 | CYP3A5 gene polymorphism affects the susceptibility to Warfarin more ... | CTD | PMID:19752777 and PMID:34382722 |
CYP3A5 | Human | XAV939 | multiple interactions | EXP | | 6480464 | [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA and [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA | CTD | PMID:34480604 |
CYP3A5 | Human | zinc atom | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Zinc deficiency results in increased expression of CYP3A9 mRNA | CTD | PMID:11705462 |
CYP3A5 | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of CYP3A5 mRNA | CTD | PMID:18593933 |
CYP3A5 | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of CYP3A5 mRNA | CTD | PMID:18593933 |
CYP3A5 | Human | zinc(0) | increases expression | ISO | Cyp3a9 (Rattus norvegicus) | 6480464 | Zinc deficiency results in increased expression of CYP3A9 mRNA | CTD | PMID:11705462 |
CYP3A5 | Human | zoledronic acid | increases expression | EXP | | 6480464 | zoledronic acid results in increased expression of CYP3A5 mRNA | CTD | PMID:24714768 |